Literature DB >> 15608477

Coagulation and fibrinolysis parameters in type 2 diabetic patients with and without diabetic vascular complications.

Cihangir Erem1, Arif Hacihasanoğlu, Sükrü Celik, Ercüment Ovali, H Onder Ersöz, Kubilay Ukinç, Orhan Deger, Münir Telatar.   

Abstract

OBJECTIVES: To investigate the markers of endogenous coagulation/fibrinolysis and vascular endothelial cell function, and to assess the relationships between hemostatic parameters and diabetic vascular complications in type 2 diabetic patients.
MATERIALS AND METHODS: Coagulation and fibrinolysis parameters were measured in 92 type 2 diabetic patients (43 male, 49 female, mean age 50.1 +/- 13.4 years) with (n = 44) and without (n = 48) vascular diabetic complications, and in 40 nondiabetic healthy subjects (20 male, 20 female, mean age 49.8 +/- 15.1 years). Common lipid parameters were also measured.
RESULTS: The plasma levels of fibrinogen, antithrombin III (AT III), plasminogen activator inhibitor-1 (PAI-1), von Willebrand factor (vWF) activity and prothrombin time were found to be significantly increased in the type 2 diabetic patients compared with the healthy subjects. Glycosylated hemoglobin lc was inversely correlated with plasma protein S and activated prothrombin time. Protein C and S activities were positively correlated with plasma vWF activity, and were negatively correlated with plasma t-PA levels. vWF activity was negatively correlated with plasma t-PA levels. AT III levels were positively correlated with plasma total cholesterol levels, plasma low density lipoprotein cholesterol levels, plasma triglycerides and D-dimer levels. Plasma PAI-1 levels and factor V activity in diabetic patients with microvascular complications were significantly higher than those of the diabetic patients without microvascular complications. The plasma PAI-1 and platelet count were increased in patients with diabetic retinopathy compared with the diabetic patients without retinopathy. Plasma PAI-1 levels and factor VII activity were significantly higher in the diabetic patients with nephropathy than in diabetic patients without nephropathy. Plasma concentrations of fibrinogen and PAI-1 were significantly higher in the diabetic patients with neuropathy than the diabetic patients without neuropathy.
CONCLUSIONS: The data demonstrated that patients with type 2 diabetes mellitus had a hypercoagulable state and hypofibrinolysis, thereby indicating that activation of coagulation with a reduced fibrinolytic activity may contribute to the increased risk of vascular disease in type 2 diabetic patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15608477     DOI: 10.1159/000081919

Source DB:  PubMed          Journal:  Med Princ Pract        ISSN: 1011-7571            Impact factor:   1.927


  32 in total

1.  The predictive role of markers of Inflammation and endothelial dysfunction on the course of diabetic retinopathy in type 1 diabetes.

Authors:  Hussein A Rajab; Nathaniel L Baker; Kelly J Hunt; Richard Klein; Patricia A Cleary; John Lachin; Gabriel Virella; Maria F Lopes-Virella
Journal:  J Diabetes Complications       Date:  2014-08-20       Impact factor: 2.852

2.  Plasma thrombin-activatable fibrinolysis inhibitor (TAFI) antigen levels in diabetic foot ulcers.

Authors:  M Erdogan; S Solmaz; A Canataroglu; M Kulaksızoglu; S Cetinkalp; A G Ozgen; F Saygili; C Yilmaz
Journal:  Endocrine       Date:  2010-04-14       Impact factor: 3.633

3.  Effect of insulin sensitizer therapy on atherothrombotic and inflammatory profiles associated with insulin resistance.

Authors:  Rozalina G McCoy; Brian A Irving; Mattias Soop; Manivanan Srinivasan; Laura Tatpati; Lisa Chow; Audrey J Weymiller; Rickey E Carter; K Sreekumaran Nair
Journal:  Mayo Clin Proc       Date:  2012-06       Impact factor: 7.616

Review 4.  Mechanisms of disease: the oxidative stress theory of diabetic neuropathy.

Authors:  Claudia Figueroa-Romero; Mahdieh Sadidi; Eva L Feldman
Journal:  Rev Endocr Metab Disord       Date:  2008-12       Impact factor: 6.514

5.  Effects of one year simvastatin and atorvastatin treatments on acute phase reactants in uncontrolled type 2 diabetic patients.

Authors:  Kubilay Ukinc; Halil Onder Ersoz; Cihangir Erem; Arif Bayram Hacihasanoglu; Suleyman Sami Karti
Journal:  Endocrine       Date:  2009-03-04       Impact factor: 3.633

6.  High risk of coagulopathy among Type-2 Diabetes Mellitus clients at a municipal hospital in Ghana.

Authors:  Richard Kd Ephraim; Yaw A Awuku; Patrick Adu; Lord Tw Ampomah; Prince Adoba; Solomon Panford; Jerry Pk Ninnoni; Hope Agbodzakey
Journal:  Ghana Med J       Date:  2017-09

7.  Blood Levels of Glycated Hemoglobin, D-Dimer, and Fibrinogen in Diabetic Retinopathy.

Authors:  Heng Zhao; Li-Dan Zhang; Li-Fang Liu; Chun-Qing Li; Wei-Li Song; Yong-Yang Pang; Yun-Liang Zhang; Dan Li
Journal:  Diabetes Metab Syndr Obes       Date:  2021-06-02       Impact factor: 3.168

8.  Diabetes and Thrombosis: A Central Role for Vascular Oxidative Stress.

Authors:  Aishwarya R Vaidya; Nina Wolska; Dina Vara; Reiner K Mailer; Katrin Schröder; Giordano Pula
Journal:  Antioxidants (Basel)       Date:  2021-04-29

9.  Inflammatory, hemostatic, and other novel biomarkers for diabetic retinopathy: the multi-ethnic study of atherosclerosis.

Authors:  Thanh T Nguyen; Ekaterina Alibrahim; F M Amirul Islam; Ronald Klein; Barbara E K Klein; Mary Frances Cotch; Steven Shea; Tien Y Wong
Journal:  Diabetes Care       Date:  2009-06-23       Impact factor: 19.112

10.  Coagulopathy and its associated factors among patients with a bleeding diathesis at the University of Gondar Specialized Referral Hospital, Northwest Ethiopia.

Authors:  Melak Aynalem; Elias Shiferaw; Yemataw Gelaw; Bamlaku Enawgaw
Journal:  Thromb J       Date:  2021-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.